<DOC>
	<DOCNO>NCT01443169</DOCNO>
	<brief_summary>This study open-label , single dose , randomize , 5-period , 5-treatment , 4-sequence cross-over fix 5th treatment arm . Subjects receive randomize sequence 330 mg CR tablet fast vitro dissolution rate , 330 mg CR tablet slow vitro dissolution rate , heavy 330 mg CR tablet fast vitro dissolution rate 330 mg market image reference CR tablet . Subjects receive 300mg IR formulation 5th period estimate compare % dose absorb versus time profile three CR prototype tablet CR reference tablet .</brief_summary>
	<brief_title>A 5-treatment , Study Healthy Volunteers Assess The Safety , Tolerability , Pharmacokinetics Four Controlled Release ( CR ) Pregabalin Tablet Formulations Immediate Release ( IR ) Formulation Administered Fasted</brief_title>
	<detailed_description />
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Subject eligibility review document appropriately qualified member investigator 's study team subject include study . Subjects must meet follow inclusion criterion eligible enrollment study : Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject legally acceptable representative . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . History febrile illness within 5 day prior first dose study medication . Subjects estimate creatinine clearance ( CLcr ) &lt; 60 mL/min derive use method Cockcroft Gault1 . Any condition possibly affect drug absorption ( eg , gastrectomy , irritable bowel syndrome ) . A positive urine drug screen . Use tobacco nicotine containing product excess equivalent 5 cigarette per day . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month Screening . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 half life precede first dose study medication . 12 lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec Screening . If QTc exceed 450 msec QRS exceed 120 msec , ECG repeat two time average three QTc QRS value use determine subject 's eligibility . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method contraception outline protocol least 14 day ( nonhormonal method ) approximately 3 month ( hormonal contraception ) prior first dose study medication 28 day last dose study medication . Use prescription ( oral , transdermal , intrauterine , implanted , injected contraceptive hormone replacement therapy ) nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose study medication . Herbal supplement must discontinue least 28 day prior first dose study medication . As exception , acetaminophen/paracetamol may use dos 1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit case case basis follow approval sponsor . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . History sensitivity pregabalin , gabapentin , alpha 2 delta ligand . History sensitivity heparin heparin induce thrombocytopenia . Unwilling unable comply Lifestyle Guidelines describe protocol . Previous participation study involve pregabalin . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Subjects active suicidal ideation suicidal behavior within 1 year prior Screening determine use CSSRS ( ColumbiaSuicide Severity Rating Scale ) active ideation identify Screening Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>relative oral bioavailability</keyword>
	<keyword>pregabalin</keyword>
</DOC>